Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Isabel, Bover"'
Autor:
Ana de Juan Ferré, Isabel Bover Barcelo, Margarita Romeo Marin, M. Gil-Martin, Aránzazu Manzano, Y. García, Lydia Gaba Garcia, Cristina Arqueros Núñez, Maria-Pilar Barretina-Ginesta, Elena García-Martínez, Antonio Gonzalez Martin, Cesar Mendiola, Maria Jesús Rubio Pérez, Ana Santaballa Bertrán
Publikováno v:
International Journal of Gynecologic Cancer. 29:1050-1056
BackgroundBevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to neoadjuvant chemotherapy before interval debulking surgery.ObjectiveTo evaluate neoadjuva
Autor:
Germana Tognon, Michel Fabbro, Ursula A. Matulonis, Kathleen N. Moore, Susana Banerjee, Mansoor Raza Mirza, Philippe Follana, Kristina Hellman, Philipp Harter, Ronnie Shapira-Frommer, Sven Mahner, Isabel Bover, Sebastien Hazard, Mario Javier Pineda, Diane Provencher, Isabel Palacio Vázquez, Robert M. Wenham, Anne Dørum, Frédéric Goffin, Anna V. Tinker
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, Elsevier, 2019, 152, pp.560-567. ⟨10.1016/j.ygyno.2018.12.009⟩
Gynecologic Oncology, Elsevier, 2019, 152, pp.560-567. ⟨10.1016/j.ygyno.2018.12.009⟩
Objective. To analyze the safety and efficacy of niraparib in patients aged >= 70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial. Methods. The trial enrolled 2 independent cohorts with histologically diagnosed recurrent ovarian, fal
Autor:
Jose Maria Del Campo, Alejandro Martínez, M. J. Rubio, Eva Guerra, Y. García, Pilar Barretina-Ginesta, Isabel Bover, Ignacio Romero, Antonio González-Martín, Ana Santaballa, Antonio Casado, Laura Vidal, Pedro Mallol, A. Arcusa, Marta Mori, Santiago González-Santiago, David Vicente, Lola Martín, Eugenia Ortega, Ana Herrero
Publikováno v:
ANTI-CANCER DRUGS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Debulking surgery, followed by taxane/platinum-based chemotherapy has traditionally been the first-line treatment for advanced ovarian cancer. However, most patients will experience recurrence afterwards, and receive subsequent lines of therapy. It h
Autor:
Jesus Garcia-Donas, Alicia Hurtado, Laia Garrigos, Ana Santaballa, Andres Redondo, Laura Vidal, Nuria Lainez, Eva Guerra, Victor Rodriguez, Juan Cueva, Isabel Bover, Isabel Palacio, Maria Jesus Rubio, Mario Prieto, Jose Antonio Lopez-Guerrero, Juan Francisco Rodriguez-Moreno, Zaida Garcia-Casado, Elena Garcia-Martinez, Alvaro Taus, Ignacio Pérez de Castro, Paloma Navarro, Susana Hernando, Enrique Grande
Publikováno v:
SSRN Electronic Journal.
Autor:
Nicoletta Colombo, Isabel Bover, Linda Van Le, C. Blakeley, Gloria S. Huang, Sudeep Karve, Sharad A. Ghamande, Andrew Green, Yann Bourhis, Philippe Huot-Marchand, Eva Chalas, Santiago González-Santiago, Begoña Graña Suárez, James Fiorica, Sandro Pignata, Giovanni Scambia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(13)
Purpose There is a growing demand for BRCA1/ 2 mutation ( BRCAm) testing in patients with ovarian cancer; however, the limited number of genetic counselors presents a potential barrier. To facilitate more widespread BRCAm testing in ovarian cancer, p
Autor:
A. Poveda Velasco, A. Gonzalez Martin, M. J. Rubio, Jinna Marcela Palacios, Ignacio A. Romero, Y. García, A. De Juan, Andrés Cervantes, Andrés Redondo, José Antonio López-Guerrero, Isabel Bover, Cesar Mendiola, J. M. Del Campo, M. Jurado
Publikováno v:
Clinical & Translational Oncology
Clinical & Translational Oncology Vol. 15 Issue 7: pp. 509-525
RODERIC. Repositorio Institucional de la Universitat de Valéncia
instname
Clinical & Translational Oncology Vol. 15 Issue 7: pp. 509-525
RODERIC. Repositorio Institucional de la Universitat de Valéncia
instname
In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first “Treatment Guidelines in Ovarian Cancer” were developed and then published in Clinical and Translational Oncology by Poveda Velasco e
Autor:
Nicoletta Colombo, Antonio González-Martín, Petronella B. Ottevanger, Lydie Bastiere-Truchot, Sandra Polleis, Anne Floquet, Isabel Bover, Maria Bjurberg, Christian Marth, Ignace Vergote, Domenica Lorusso, Carmen Schade-Brittinger, Andreas du Bois, Sven Mahner, Josep M. del Campo, Nicolas Martin, Astrid Kiermaier, Mikkel Z. Oestergaard, Patricia Pautier, Christian Kurzeder, Frederik Marmé, Joern Rau, Pilar Barretina-Ginesta
Purpose The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fad8a2a45ca299f3ca71e16c850cc444
http://hdl.handle.net/10281/129111
http://hdl.handle.net/10281/129111
Autor:
Fiona H Blackhall, Joe O'Connell, Stephen P. Letrent, Dae Seog Heo, Isabel Bover, Denis C. Talbot, Maciej Krzakowski, Richard G. Frank, Michael Boyer, Ian Taylor, Carlos H. Barrios, A. Campbell, Ana Ruiz-Garcia, Rafael Rosell, Jane Q. Liang, Suresh S. Ramalingam, Keunchil Park
Publikováno v:
Journal of Clinical Oncology. 30:3337-3344
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non
Autor:
A. De Juan, M. J. Rubio, Antonio González-Martín, E. Ortega, A. Garcia-Arias, Ana Oaknin, Andrés Redondo, M. Gil-Martin, Isabel Bover, J. F. Cueva Bañuelos
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Clinical & Translational Oncology
Consejería de Sanidad de la Comunidad de Madrid
Clinical & Translational Oncology
Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37735d6da1de1db82a6e462d9b6612bc
https://hdl.handle.net/20.500.13003/10590
https://hdl.handle.net/20.500.13003/10590
Autor:
Susana Benlloch, Carlos Camps, Rafael Sirera, Carlota Costa, Miguel Angel Molina-Vila, Jose L uis Ramirez-Serrano, Ana Giménez-Capitán, Christian Rolfo, Rafael Rosell, Eloisa Jantus-Lewintre, Miguel Taron, Sara Simonetti, Imane Chaib, Pedro Mendez, Isabel Bover
Publikováno v:
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
instname
instname
The majority of non-small-cell lung cancer (NSCLC) patients present with locally advanced (35%) or metastatic disease (40%); in this setting, it is of the utmost importance to balance efficacy with toxicity. However, with platinum combinations, survi